Zacks: Pharma Mar (PHMMF) Given Consensus Recommendation of “Strong Buy” by Analysts
Pharma Mar (NASDAQ:PHMMF) has received a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.
Zacks has also assigned Pharma Mar an industry rank of 113 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research raised Pharma Mar from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a research note on Wednesday, May 24th.
TRADEMARK VIOLATION WARNING: “Zacks: Pharma Mar (PHMMF) Given Consensus Recommendation of “Strong Buy” by Analysts” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/zacks-pharma-mar-phmmf-given-consensus-recommendation-of-strong-buy-by-analysts/1488207.html.
Shares of Pharma Mar (NASDAQ:PHMMF) traded up 2.042% during mid-day trading on Monday, hitting $4.398. The stock had a trading volume of 17,342 shares. The company’s market cap is $1.09 billion. Pharma Mar has a 12 month low of $2.40 and a 12 month high of $4.80. The stock’s 50-day moving average is $4.47 and its 200 day moving average is $3.86.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with Analyst Ratings Network's FREE daily email newsletter.